Table of Contents
Epilepsy Research and Treatment
Volume 2015 (2015), Article ID 415082, 6 pages
Research Article

Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures

1Cipla Ltd, 117/1, Anjanadri, Pantharapalya, Bangalore 560039, India
2Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, No. 82 EPIP Area, Whitefield, Bangalore 560037, India
3Department of Neurology, Columbia Asia Hospital, Whitefield, Bangalore 560066, India

Received 31 August 2015; Accepted 1 December 2015

Academic Editor: Roy G. Beran

Copyright © 2015 Swaroop Hassan Suresh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. Levetiracetam (LEV) is a newer antiepileptic drug with better pharmacokinetic profile. Currently, it is frequently used for the treatment of partial seizures. The present study was undertaken to compare the efficacy and safety of LEV and Carbamazepine (CBZ) in partial epilepsy. Methods. This was a prospective, open labeled, randomized study. It was conducted in participants suffering from partial seizures after the approval of ethics committee and written informed consent. The first group received Tab LEV (500 to 3000 mg/day) and the second group received Tab CBZ (300 to 600 mg/day). The primary outcomes were efficacy and safety. The secondary outcome was the Quality of Life (QOL). Efficacy was assessed by comparing the seizure freedom rates at the end of 6 months. Safety profile was evaluated by comparing the adverse effects. QOL was assessed by QOLIE-10 scale. Results. The overall seizure freedom rate at the end of 6 months was 71.42% in CBZ group compared to 78.57% in LEV group (). Both LEV and CBZ reported a similar incidence of adverse reactions. LEV group reported more behavioral changes like increased aggression and anxiety. Also, it showed better QOL compared to the CBZ group. Conclusion. LEV monotherapy and CBZ monotherapy demonstrated similar efficacy for treatment of partial epilepsy and were found to be well tolerated.